---
title: "UR Sugar Industries Ltd (539097) — Share Price, Financials & Analysis"
symbol: "539097"
company: "UR Sugar Industries Ltd"
canonical: "https://tapetide.com/stocks/539097"
isin: "INE904R01027"
nse_symbol: "HKGLTD"
bse_code: "539097"
sector: "Commercial Services"
industry: "Trading & Distributors"
market_cap_cr: 15.79
generated_at: "2026-09-13T19:45:03.266Z"
---

# UR Sugar Industries Ltd (539097)

Canonical page: https://tapetide.com/stocks/539097

## Company

- **NSE Symbol:** HKGLTD
- **BSE Code:** 539097
- **ISIN:** INE904R01027
- **Sector:** Commercial Services
- **Industry:** Trading & Distributors
- **Macro Sector:** Services
- **Stock Type:** EQUITY
- **Listed Since:** 2015-04-15
- **Face Value:** ₹2
- **F&O Eligible:** No
- **Website:** hkglimited.com

## About

Incorporated in 2010, UR Sugar Industries 
Ltd provides midstream services for sugar production[1]

## Latest Price

## Key Fundamentals

Observed at 2026-09-11T04:50:59.330419Z.

- **Market Cap:** ₹15.79 Cr
- **Classification:** Microcap
- **P/E (reported):** 33.8
- **EPS (TTM):** ₹0.08
- **EPS (reported):** ₹0
- **Book Value:** ₹3.57
- **Price to Book:** 0.85
- **Dividend Yield:** 0%
- **ROE:** -1.39%
- **ROCE:** -1.4%
- **Debt to Equity:** 0
- **Revenue (yearly):** ₹9.2 Cr
- **Net Income:** ₹-0.2 Cr
- **EBITDA:** ₹-0.1 Cr
- **52-Week High:** ₹5.36
- **52-Week Low:** ₹1.81
- **RSI (14):** 43.22

## Tapetide Score

- **Score:** 56 / 100
- **Score date:** 2026-09-04
- **Archetype:** Trend Ahead of Fundamentals
- **What it means:** The price trend is running ahead of what the financials currently support. Moves like this depend on the fundamentals catching up; check what would have to be true for that.
- **Pillar profile:** Quality: Weak · Valuation: Expensive · Momentum: Rising
- **Percentile:** 74.1 (of 4473 scored stocks)
- **Confidence:** 82%
- **Data coverage:** 81%

| Pillar | Score | Weight |
| --- | --- | --- |
| financial health | 86.12 | 9.89% |
| momentum | 94.5 | 13.19% |
| ownership | 55.02 | 26.37% |
| quality | 49.73 | 24.18% |
| valuation | 34.07 | 26.37% |

The Tapetide Score is decision-support only, not investment advice.

## Key Insights

### Strengths

- Company is almost debt free.
- Stock is trading at 0.85 times its book value

### Weaknesses

- Though the company is reporting repeated profits, it is not paying out dividend
- Promoter holding is low: 26.7%
- Company has a low return on equity of 2.61% over last 3 years.

## Growth Rates

| Metric | QoQ | 1Y | 3Y | 5Y |
| --- | --- | --- | --- | --- |
| cash flow growth | — | -100% | 100% | -100% |
| ebitda margin growth | 0% | -277.14% | -639.13% | — |
| net income growth | 0% | -300% | 59% | -9% |
| revenue growth | 0.1% | -72.04% | -51.75% | — |
| roce | -9.52% | -176.92% | -172.92% | — |
| roe | 5.88% | -202.96% | 0.39% | — |

## Financial Statements

### Quarterly Results

All figures in ₹ crore unless the row name says otherwise.

| Item | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Expenses | 0.08 | 0.09 | 0.48 | 0.05 | 0.05 | 0.07 | 0.08 | 0.06 | 0.06 | 0.14 | 0.09 | 0.05 |
| Operating Profit | -0.08 | -0.09 | -0.48 | -0.05 | -0.05 | -0.07 | -0.08 | -0.06 | -0.06 | -0.14 | -0.09 | -0.05 |
| Other Income | 1.07 | 0.29 | 0.24 | 0.24 | 0 | 0.2 | 0.37 | 0.23 | 0.23 | 0.25 | 0.24 | 0.23 |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Depreciation | 0.02 | 0.01 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit before tax | 0.97 | 0.19 | -0.24 | 0.19 | -0.05 | 0.13 | 0.29 | 0.17 | 0.17 | 0.11 | 0.15 | 0.18 |
| Tax % | 22.68 | 52.63 | -29.17 | 36.84 | -80 | 23.08 | 24.14 | 23.53 | 23.53 | 27.27 | 26.67 | 22.22 |
| Net Profit | 0.76 | 0.08 | -0.17 | 0.11 | 0 | 0.09 | 0.22 | 0.13 | 0.12 | 0.08 | 0.11 | 0.13 |
| EPS in Rs | 0.14 | 0.02 | -0.03 | 0.02 | 0 | 0.02 | 0.04 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |

### Profit & Loss

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sales | 4.36 | 7.85 | 0.91 | 6.63 | 6.79 | 9.03 | 0.05 | 0 | 0 | 0 |
| Expenses | 4.92 | 8.09 | 2.79 | 5.75 | 5.28 | 9.25 | 0.76 | 0.25 | 0.35 | 0.34 |
| Operating Profit | -0.56 | -0.24 | -1.88 | 0.88 | 1.51 | -0.22 | -0.71 | -0.25 | -0.35 | -0.34 |
| OPM % | -12.84 | -3.06 | -206.59 | 13.27 | 22.24 | -2.44 | -1420 | — | — | — |
| Other Income | 0.88 | -0.64 | 0.03 | 0 | 0.07 | 0.13 | 1.57 | 0.81 | 0.95 | 0.95 |
| Interest | 0 | 0 | 0 | 0 | 0.05 | 0.01 | 0.01 | 0 | 0 | 0 |
| Depreciation | 0.1 | 0.03 | 0.03 | 0.01 | 0.13 | 0.13 | 0.05 | 0 | 0 | 0 |
| Profit before tax | 0.22 | -0.91 | -1.88 | 0.87 | 1.4 | -0.23 | 0.8 | 0.56 | 0.6 | 0.61 |
| Tax % | 0 | -1.1 | 0 | 17.24 | -5.71 | -8.7 | 31.25 | 25 | 25 | — |
| Net Profit | 0.22 | -0.9 | -1.89 | 0.71 | 1.47 | -0.22 | 0.56 | 0.42 | 0.44 | 0.44 |
| EPS in Rs | 0.04 | -0.17 | -0.36 | 0.13 | 0.28 | -0.04 | 0.11 | 0.08 | 0.08 | 0.08 |
| Dividend Payout % | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — |

### Balance Sheet

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Equity Capital | 3.5 | 3.5 | 3.5 | 3.5 | 3.5 | 10.5 | 10.5 | 10.5 | 10.5 | 10.5 |
| Reserves | 1.13 | 1.36 | 0.45 | -1.44 | -0.73 | 7.57 | 7.1 | 7.66 | 7.65 | 8.1 |
| Borrowings | 0.03 | 0.02 | 0 | 0 | 0 | 0.12 | 0.1 | 0 | 0 | 0 |
| Other Liabilities | 1.26 | 0.57 | 0.02 | 0.02 | 0.22 | 0.17 | 0.08 | 0.67 | 0.29 | 0.2 |
| Total Liabilities | 5.92 | 5.45 | 3.97 | 2.08 | 2.99 | 18.36 | 17.78 | 18.83 | 18.44 | 18.8 |
| Fixed Assets | 0.35 | 0.16 | 0.05 | 0.02 | 0.21 | 0.33 | 0.2 | 1.75 | 3.07 | 3.07 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 1.54 | 3.17 | 0.62 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Other Assets | 4.03 | 2.12 | 3.3 | 2.06 | 2.78 | 17.03 | 17.58 | 17.08 | 15.37 | 15.73 |
| Total Assets | 5.92 | 5.45 | 3.97 | 2.08 | 2.99 | 18.36 | 17.78 | 18.83 | 18.44 | 18.8 |

### Cash Flow

All figures in ₹ crore unless the row name says otherwise.

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Cash from Operating Activity | 0.77 | 1.08 | -2.51 | -0.8 | 0.33 | -1.15 | -8.59 | 12.73 | -1.04 | -0.69 |
| Cash from Investing Activity | -0.42 | -1.43 | 2.68 | 0.64 | -0.2 | -9.21 | 5.45 | -12.45 | 0.51 | 0.72 |
| Cash from Financing Activity | -0.01 | -0.01 | -0.01 | 0 | 0 | 13.95 | -0.24 | -0.13 | 0 | 0 |
| Net Cash Flow | 0.34 | -0.36 | 0.16 | -0.17 | 0.12 | 3.58 | -3.38 | 0.15 | -0.53 | 0.03 |
| Free Cash Flow | 0.76 | 1.21 | -2.44 | -0.8 | 0.13 | -1.4 | -8.6 | 11.18 | -2.36 | -0.69 |
| CFO/OP | 856 | -193 | 1046 | 43 | 38 | -52 | 3859 | -1755 | 356 | 126 |

### Ratios

| Item | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Debtor Days | 7.69 | 49.39 | 5.11 | 0 | 0 | 17.74 | 0 | 0 | — | — |
| Inventory Days | 28.31 | 46.43 | 98.13 | 167.29 | 124.97 | 314.53 | 0 | — | — | — |
| Days Payable | 13.65 | 0 | 0 | 1.38 | 1.98 | 4.51 | — | — | — | — |
| Cash Conversion Cycle | 22.35 | 95.82 | 103.24 | 165.91 | 122.99 | 327.76 | 0 | 0 | — | — |
| Working Capital Days | 25.73 | 120.55 | 140.89 | 786.15 | 128.82 | 268.78 | 540.43 | -2117 | — | — |
| ROCE % | 1.13 | 2.94 | -20.61 | -62.56 | 36.02 | 13.84 | -1.23 | 4.52 | 3.08 | 3.27 |

## Shareholding Pattern

### Quarterly

| Category | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Promoters | 26.67% | 26.67% | 26.67% | 26.67% | 26.67% | 26.67% | 26.67% | 26.86% | 26.67% | 26.67% | 26.67% | 26.67% |
| FIIs | 0% | 0% | 0% | 0% | 0.19% | 0.19% | 0.19% | 0% | 0% | 0% | 0% | 0.21% |
| DIIs | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Government | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
| Public | 61.07% | 61.3% | 59.15% | 57.52% | 58.34% | 57.51% | 60.07% | 58.02% | 60.79% | 61.52% | 59.81% | 60% |
| Others | 12.26% | 12.03% | 14.18% | 15.81% | 14.8% | 15.64% | 13.07% | 15.12% | 12.54% | 11.81% | 13.52% | 13.12% |
| No. of Shareholders | 4058 | 4386 | 4984 | 5529 | 6458 | 6865 | 6996 | 6898 | 7105 | 7356 | 7459 | 7859 |

## Technical Indicators

Derived from daily closing prices and recomputed each trading session; values move with the market.

- **Overall Signal:** Neutral
- **Buy / Neutral / Sell:** 8 / 3 / 8

### Moving Averages — summary: **Strong Sell**

| Indicator | Value | Signal |
| --- | --- | --- |
| SMA (10) | 3.35 | Sell |
| EMA (10) | 3.28 | Sell |
| SMA (20) | 3.43 | Sell |
| EMA (20) | 3.29 | Sell |
| SMA (50) | 3.02 | Buy |
| EMA (50) | 3.12 | Sell |
| SMA (100) | 2.94 | Buy |
| EMA (100) | 3.03 | Buy |
| SMA (200) | 2.97 | Buy |
| EMA (200) | 3.3 | Sell |

### Oscillators — summary: **Buy**

| Indicator | Value | Signal |
| --- | --- | --- |
| RSI (14) | 43.22 | Neutral |
| MACD (12,26,9) | 0.05 | Sell |
| Stochastic (14,3,3) | 3.84 | Buy |
| ADX (14) | 26.64 | Buy |
| Williams %R (14) | -92.11 | Buy |
| ATR (14) | 0.28 | High Volatility |
| ROC (12) | -18.72 | Sell |
| Stoch RSI (14) | 0 | Buy |
| UO (7,14,28) | 34.33 | Neutral |

## Filings & Documents

### Exchange Filings & Announcements

| Date | Document |
| --- | --- |
| 2026-09-03 | [Shareholder Meeting On Friday 25Th September 2026 At The Registered Office Of The Company](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=f1b8a5cf-71cd-4a3b-b016-d244b7e28f3e.pdf) |
| 2026-09-03 | [Reg. 34 (1) Annual Report.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5c0d219e-0b9a-4f96-a525-8056a73d687f.pdf) |
| 2026-09-03 | [Compliances-Reg. 50 (2) - Intimation to the Exchange about meeting under 50(2)](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=edc4a17a-c334-44c7-87a4-2ea0517664a2.pdf) |
| 2026-09-03 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=7476cedd-f525-41c1-a343-e702f7bd5bae.pdf) |
| 2026-09-02 | [Board Meeting Outcome for Outcome Of The Meeting Of Board Of Directors Held On 02Nd September 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=0fa2ed50-3234-450c-8dea-7482aef68d07.pdf) |
| 2026-09-02 | [Intimation Related To Record Date And Cut-Off Date For The Purpose Of 16Th Annual General Meeting](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=41ef49e4-310e-4d43-96fb-8b29ac4e568c.pdf) |
| 2026-08-25 | [BSE Email Ref No. L/SURV/ONL/PV/SG/ 2026-2027 / 300 Dated August 25 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=b59af025-2f11-44ee-ac14-0af683c0c629.pdf) |
| 2026-08-25 | [Closure of Trading Window](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=8aa74a54-15a8-4146-a90d-72ba9a7f4509.pdf) |
| 2026-08-25 | [Board Meeting Intimation for Intimation Of Board Meeting To Be Held On Wednesday September 02 2026 At 11:00 A.M.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=41bacec2-8beb-4b5e-8b67-57acf849d445.pdf) |
| 2026-08-12 | [Announcement under Regulation 30 (LODR)-Newspaper Publication](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=cbac0e39-d70c-440a-8f84-fcfd6883e318.pdf) |

### Other Documents

| Date | Document |
| --- | --- |
| 31 Mar - Trading window closed from April 1, 2026; reopens 48 hours after FY2026 results publication. | [Closure of Trading Window 31 Mar - Trading window closed from April 1, 2026; reopens 48 hours after FY2026 results publication.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1044d098-58db-4111-b664-98f034b8c361.pdf) |
| 3 Mar - Natco launches generic Pomalidomide in U.S.; $3.2bn market; 180-day shared exclusivity. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 3 Mar - Natco launches generic Pomalidomide in U.S.; $3.2bn market; 180-day shared exclusivity.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/a5ea62bc-df3a-437a-8d62-61601cd4d40f.pdf) |
| 3 Feb - Board meeting Feb 11, 2026 to approve unaudited Q3 (Dec 31, 2025) results. | [Board Meeting Intimation for Quarterly Results For The Quarter Ended 31St December 2025 3 Feb - Board meeting Feb 11, 2026 to approve unaudited Q3 (Dec 31, 2025) results.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/f49f08f5-53b3-4986-906c-098e3f553d3c.pdf) |
| 25 Feb - NATCO Pharma informs BSE (25 Feb 2026) it disclosed all price-sensitive information; volume rise market-driven. | [Clarification On Volume Movement Of Shares 25 Feb - NATCO Pharma informs BSE (25 Feb 2026) it disclosed all price-sensitive information; volume rise market-driven.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/8dee0d02-5c44-4df0-9acf-5e506bc988f2.pdf) |
| 25 Feb - Confirms CDSCO Semaglutide approval Feb 14, 2026; launch planned March 2026; Eris partnership; no material financial impact. | [Rumour verification - Regulation 30(11) 25 Feb - Confirms CDSCO Semaglutide approval Feb 14, 2026; launch planned March 2026; Eris partnership; no material financial impact.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/3c1ef757-0547-4dc7-af6b-164823c4135e.pdf) |
| 17h - Investor meeting with Investec Promoter & Founder group on 9 March 2026, Mumbai, 09:00–17:00. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 17h - Investor meeting with Investec Promoter & Founder group on 9 March 2026, Mumbai, 09:00–17:00.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/a31b773e-4561-4438-a789-78429ae1e74e.pdf) |
| 14 Feb - CDSCO approves NATCO's generic Semaglutide injection; launch planned March 2026. | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 14 Feb - CDSCO approves NATCO's generic Semaglutide injection; launch planned March 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachHis/b6c90a85-70f8-463c-9d7e-ac74e6aeb477.pdf) |
| 13 Feb - FDA EIR: Manali Chennai API inspection (Nov 17–21, 2025); 7 Form‑483 observations; classified Voluntary Action Indicated (VAI). | [Announcement under Regulation 30 (LODR)-Press Release / Media Release 13 Feb - FDA EIR: Manali Chennai API inspection (Nov 17–21, 2025); 7 Form‑483 observations; classified Voluntary Action Indicated (VAI).](https://www.bseindia.com/xml-data/corpfiling/AttachLive/0a3a50f2-000f-4039-a3e4-cbe0b879956d.pdf) |
| 12 Feb - Audio of Q3 FY26 earnings call (quarter/nine months ended Dec 31, 2025) uploaded Feb 12, 2026. | [Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 12 Feb - Audio of Q3 FY26 earnings call (quarter/nine months ended Dec 31, 2025) uploaded Feb 12, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/ec2824b7-a917-4b22-a59a-66dfc9532dd8.pdf) |
| 12 Feb - 3rd interim dividend Rs1.50/share (75%); record date Feb 18, 2026; payment from Feb 26, 2026. | [Corporate Action-Board approves Dividend 12 Feb - 3rd interim dividend Rs1.50/share (75%); record date Feb 18, 2026; payment from Feb 26, 2026.](https://www.bseindia.com/xml-data/corpfiling/AttachLive/7d14c90b-e418-4f7a-9951-0a2e217efe05.pdf) |

### Results & Financial Statements

| Date | Document |
| --- | --- |
| 2026-08-10 | [Results- For The Quarter Ended 30Th June 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=5c70acc8-cb2a-4db1-8d35-eb2e3ae09c38.pdf) |
| 2026-05-19 | [Financials Results For Quarter And Year Ended 31St March 2026](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ae7ab5bd-36d0-49a2-8c94-c6216e3f46d0.pdf) |
| 2026-02-11 | [Financial Results For Quarter Ended 31.12.2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=465bfdce-019c-4227-af50-337c1a1cd143.pdf) |
| 2026-02-11 | [Financial Results For Quarter Ended 31.12.2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=2a6a5be2-e6ff-4e5a-b583-9dc4fa5845b7.pdf) |
| 2025-11-12 | [Outcome Of The Meeting Of Board Of Directors Held On 12Th November 2025.](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=c9d50a69-9551-4e30-8b87-aca53af7bc17.pdf) |
| 2025-08-07 | [Results- Financials Results For June 30 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=af767b20-fe31-4084-8fbf-958a15dbeb96.pdf) |
| 2025-05-26 | [Outcome Of The Meeting Of Board Of Directors Held On 26Th May 2025](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=40eaf233-9885-44c6-9f7d-c676c2bde367.pdf) |
| 2025-02-07 | [Results- December 31 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ef8b6d25-f6c6-4c84-a48b-ccef8860eae1.pdf) |
| 2024-11-13 | [Results- Unaudited Financials Results For Quarter Ended 30.09.2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=323ce57e-fea6-45fc-ba1d-cc8df01e8714.pdf) |
| 2024-08-08 | [Results-Financial Results For Quarter Ended June 30Th, 2024](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=3da29604-c34f-4eeb-8ccc-297cfd2acff1.pdf) |

### Earnings Call Documents

| Date | Document |
| --- | --- |
| Sep 2019 | [Concall - Sep 2019](https://www.bseindia.com/xml-data/corpfiling/AttachHis/7f23fe19-9b07-42d3-a3e8-e772768af0c3.pdf) |
| Sep 2016 | [Concall - Sep 2016](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=75B670DD_17EE_4601_89BD_8426710FF1A0_154627.pdf) |
| Nov 2025 | [Concall - Nov 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ac8f848f-8703-4403-9ae3-cb2d420d47da.pdf) |
| Nov 2024 | [Concall - Nov 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/bfa2b366-9531-46e4-a6e5-1be622bc6b51.pdf) |
| Nov 2023 | [Concall - Nov 2023](https://www.bseindia.com/xml-data/corpfiling/AttachHis/69ef4068-751c-4c97-ae82-a551c697e63b.pdf) |
| Nov 2022 | [Concall - Nov 2022](https://www.bseindia.com/xml-data/corpfiling/AttachHis/269dbb1f-c0d4-45c4-bdbf-e77835b39c5d.pdf) |
| Nov 2016 | [Concall - Nov 2016](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=B5E17E38_32ED_424A_9786_CF991F61235A_153000.pdf) |
| May 2024 | [Concall - May 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/92ba56ca-3913-4cf9-8a4e-8ced6baa567d.pdf) |
| Jun 2025 | [Concall - Jun 2025](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d43e2593-6819-4d99-b9a6-c3019c901490.pdf) |
| Jun 2024 | [Concall - Jun 2024](https://www.bseindia.com/xml-data/corpfiling/AttachHis/99cc0f91-9fd5-4d78-b404-a4e50d143d60.pdf) |

### Annual Reports

| Date | Document |
| --- | --- |
| from nse | [Financial Year 2013 from nse](https://archives.nseindia.com/annual_reports/AR_2233_NATCOPHARM_2012_2013_10102013100302.zip) |
| from bse | [Financial Year 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/08737473-9fef-496b-881b-746b8ab600b1.pdf) |
| from bse | [Annual Report 2025 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/ffa7e9ca-4f17-4ab3-b710-9f5cad4529b9.pdf) |
| from bse | [Financial Year 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/d5a992a3-1b5a-44b4-8e5b-343b600e56fc.pdf) |
| from bse | [Annual Report 2024 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/1b5193ee-10e5-47c2-9a37-f4d24c72f8e9.pdf) |
| from bse | [Financial Year 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/76692336-a42d-46bd-aa85-16fbb9846663.pdf) |
| from bse | [Annual Report 2023 from bse](https://www.bseindia.com/xml-data/corpfiling/AttachHis/2ca5936d-8e19-4ebc-bc1f-52b4d83c363a.pdf) |
| from bse | [Financial Year 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/524816/75411524816.pdf) |
| from bse | [Annual Report 2022 from bse](https://www.bseindia.com/bseplus/AnnualReport/539097/77005539097_20_09_22.pdf) |
| from bse | [Financial Year 2021 from bse](https://www.bseindia.com/bseplus/AnnualReport/524816/70606524816.pdf) |

### Investor Presentations

| Date | Document |
| --- | --- |
| 2022-04-06 | [Announcement under Regulation 30 (LODR)-Investor Presentation](https://www.bseindia.com/stockinfo/AnnPdfOpen.aspx?Pname=ebe86211-955f-456f-896f-d5762c2f419a.pdf) |

---

Provenance differs by section. Financial statements, shareholding and filings are as reported in company disclosures to NSE/BSE/SEBI. Price, volume and 52-week levels are exchange market data. Technical indicators are computed by Tapetide from daily closing prices. The Tapetide Score is Tapetide's own analysis. Analyst ratings are third-party estimates, not company statements. All figures are for research and information only and are not investment advice. Generated 2026-09-13T19:45:03.266Z.